Patents Assigned to Yeda Research and Development Co., Ltd.
-
Patent number: 12046371Abstract: Method of predicting a response of a subject to food is disclosed. The method comprises: selecting a food to which a response of the subject is unknown; accessing a first database having data describing the subject but not a response of the subject to the selected food; accessing a second database having data pertaining to responses of other subjects to foods, the responses of the other subjects including responses of at least one other subject to the selected food or a food similar to said selected food; and analyzing the databases based on the selected food to estimate the response of the subject to the selected food.Type: GrantFiled: March 20, 2023Date of Patent: July 23, 2024Assignee: Yeda Research and Development Co. Ltd.Inventors: Eran Segal, Eran Elinav
-
Patent number: 12041907Abstract: Provided herein are genetically modified cells and genetically modified plants having increased or decreased expression of a cellulose synthase like G (CSLG) enzyme. These cells and plants may have an increased or decreased content a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin, compared to a corresponding unmodified cell or plant. Also provided herein are methods of producing a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin in a genetically modified cell, as well as methods of reducing the content of a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin in a cell of a plant or a plant part, and methods of increasing the content of a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin in a cell of a plant or a plant part.Type: GrantFiled: September 5, 2019Date of Patent: July 23, 2024Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Asaph Aharoni, Prashant Sonawane, Maxim Itkin, Adam Jozwiak
-
Publication number: 20240239886Abstract: Provided are antibodies to TREM2 and Gpnmb. Also provided are compositions comprising the antibodies and methods of using same.Type: ApplicationFiled: February 5, 2024Publication date: July 18, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Ido AMIT, Chamutal BORNSTEIN-OVITS, Adam YALIN, Adi MOSHE, Oren BARBOY, Assaf WEINER, Yonatan KATZENELENBOGEN, Diego JAITIN, Fadi SHEBAN
-
Patent number: 12038436Abstract: Assays and methods for diagnosing and treating autoimmune diseases. Particularly, the invention provides methods for differential diagnosis of specific autoimmune diseases, including autoimmune rheumatic disorders.Type: GrantFiled: September 29, 2022Date of Patent: July 16, 2024Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Rachel Sorek, Keren Jakobi-Brook, Pennina Safer, Irun R Cohen
-
Publication number: 20240229221Abstract: This invention provides a process for the preparation of aluminum scandium nitride films. This invention further provides Caluminum scandium nitride films and layers, and devices and systems comprising aluminum scandium nitride films.Type: ApplicationFiled: May 12, 2022Publication date: July 11, 2024Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Igor LUBOMIRSKY, David EHRE, Asaf COHEN
-
Publication number: 20240228521Abstract: Disclosed herein are 3, 4-didehydro- and 3?-deoxy-3, 4-didehydro-compounds, and pharmaceutical compositions thereof. The 3, 4-didehydro- and 3?-deoxy-3, 4-didehydro-compounds, and pharmaceutical compositions thereof may be used in methods of treating diseases including virus-induced diseases, cancer, autoimmune diseases, immune disorders, and bacterial-associated diseases or infections, or combinations thereof. Examples of viral-induced diseases include viral infections by RNA or DNA viruses, for example SARS-CoV-2, EBV, and BKV.Type: ApplicationFiled: April 14, 2022Publication date: July 11, 2024Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: David SPERANDIO, Helena SHOMAR MONNGES, Eugene J. EISENBERG, Arthur MACHLENKIN
-
Patent number: 12031138Abstract: A microorganism which is genetically modified so that it produces a first essential biomass precursor by metabolizing CO2 using a recombinant carbon fixation enzyme is disclosed. The microorganism produces a second biomass precursor by metabolizing an organic carbon source and not by metabolizing CO2. The microorganism does not use the organic carbon source for producing the first essential biomass precursor.Type: GrantFiled: March 25, 2019Date of Patent: July 9, 2024Assignee: Yeda Research and Development Co. Ltd.Inventors: Ron Milo, Niv Antonovsky, Elad Noor, Arren Bar-Even, Yehudit Zohar, Lior Zelcbuch, Shmuel Gleizer, Shira Amram
-
Patent number: 12020120Abstract: A quantum computing system includes a first resonator couplable to a first alkali atom, a second resonator couplable to a second alkali atom, and lasers for trapping, cooling, and manipulating the first alkali atom and the second alkali atom. Detectors detect a presence of the trapped first alkali atom and the trapped second alkali atom, and a processor is configured to receive at least one input signal from at least one of the detectors, the input signal indicating a presence of the trapped first alkali atom and the trapped second alkali atom, and, based on the received input, control at least some of the lasers to manipulate at least one of the trapped first alkali atom and the trapped second alkali atom to thereby generate photonic qubits using the trapped first alkali atom or generate entanglement between photonic qubits transmitted to the trapped second alkali atom.Type: GrantFiled: October 10, 2023Date of Patent: June 25, 2024Assignees: Yeda Research and Development Co. Ltd., Quantum Source Labs Ltd.Inventors: Gil Semo, Ziv Aqua, Oded Melamed, Dan Charash, Serge Rosenblum, Barak Dayan
-
Publication number: 20240197746Abstract: A method of treating colorectal cancer (CRC) is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a Mitogen/extracellular signal-regulated kinase (MEK) inhibitor and a SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase (SRC) inhibitor, wherein cancer cells of the subject express an amount of SRC p419 above a predetermined level and do not express a KRAS G12 mutation, thereby treating the CRC.Type: ApplicationFiled: February 28, 2024Publication date: June 20, 2024Applicants: Yeda Research and Development Co. Ltd., The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterInventors: Ravid STRAUSSMAN, Nancy GAVERT, Yaara ZWANG
-
Publication number: 20240204171Abstract: Provided herein noncovalent hybrids comprising carbon nanotubes (CNTs) and aromatic compounds, composites based on them, process of preparation and uses thereof, e.g. as electrodes and in lithium-ion cells; wherein the hybrids possess superior mechanical and electrical properties.Type: ApplicationFiled: February 18, 2024Publication date: June 20, 2024Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Boris RYBTCHINSKI, Aayan MAITY, Haim WEISSMAN, Michal LESKES
-
Publication number: 20240182566Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.Type: ApplicationFiled: December 11, 2023Publication date: June 6, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
-
Publication number: 20240180966Abstract: A method of treating cancer in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a population of T cells, wherein an alpha chain of a TCR of at least 10% of the T cells of the population has a CDR3 amino acid sequence as set forth in SEQ ID NO: 6, and a beta chain of the CDR has a CDR3 amino acid sequence as set forth in SEQ ID NO: 7.Type: ApplicationFiled: October 27, 2023Publication date: June 6, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Yardena SAMUELS, Nir FRIEDMAN, Aviyah PERI, Erez GREENSTEIN, Michal ALON
-
Publication number: 20240165027Abstract: Formulations (e.g., solutions) comprising one or more water-soluble polymer(s), liposomes, and an aqueous carrier, are provided. The provided solutions are useful for rinsing, and/or immersing therein, a contact lens and/or in the treatment of ocular discomfort, for example, an ocular discomfort associated with a contact lens. Also provided are kits comprising the solution and a contact lens; articles-of-manufacturing comprising the solution and configured for dispending the solution; and methods utilizing the solution.Type: ApplicationFiled: January 29, 2024Publication date: May 23, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Jacob KLEIN, Ronit GOLDBERG, Jasmine SEROR
-
Publication number: 20240167176Abstract: The present invention provides a stirring-free scalable electrochemical reactor enabled by alternating current and uses thereof in a method of performing electrosynthesis of organic reaction.Type: ApplicationFiled: October 19, 2023Publication date: May 23, 2024Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Sergey N. SEMENOV, Evgenil BORTNIKOV
-
Publication number: 20240166768Abstract: Monoclonal antibodies for the treatment of ovarian cancer are provided also provide are uses of same. Such uses include characterizing the tumor, diagnosing it and treatment of same.Type: ApplicationFiled: February 2, 2024Publication date: May 23, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Irit SAGI, Roei David MAZOR, Ziv SHULMAN
-
Patent number: 11986488Abstract: A method of treating a malignant disease involving T cell exhaustion in a subject, with the proviso that said malignant disease is not a B cell malignancy, is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84, thereby treating the malignant disease involving the T cell exhaustion. Also disclosed is a method of treating an autoimmune or inflammatory disease in a subject, the method comprising administering to a subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84. A method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of SLAMF1, with the proviso that said agent is not an agent capable of decreasing an activity or expression of CD84, is also disclosed.Type: GrantFiled: November 5, 2020Date of Patent: May 21, 2024Assignee: Yeda Research and Development Co. Ltd.Inventors: Idit Shachar, Hadas Lewinsky, Lihi Radomir, Anna Wiener
-
Publication number: 20240156959Abstract: A method of treating cancer in a subject in need thereof is disclosed wherein cancer cells of the subject express an EGFR having a mutation in a kinase domain of the receptor. The method comprises administering to the subject a therapeutically effective amount of: (i) an anti-epidermal growth factor receptor (anti-EGFR) antibody; (ii) an AXL inhibitor, and optionally (iii) a tyrosine kinase inhibitor (TKI). Also disclosed is a new anti-AXL antibody.Type: ApplicationFiled: December 19, 2023Publication date: May 16, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Yosef YARDEN, Ashish NORONHA
-
Patent number: 11982566Abstract: A system for photon correlation of an illuminated object and/or a light source is provided. The system includes a light source for illuminating the object and an optical system having an object-facing side configured to face the object or the light source and a projection side with the projection side having a focal plane. The system also includes a single-chip single photon avalanche photodiode (SPAD) array arranged at the focal plane and a timing circuit associated with the single-chip SPAD array for measuring arrival times of photons detected by the single-chip SPAD array.Type: GrantFiled: February 28, 2020Date of Patent: May 14, 2024Assignees: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL), YEDA RESEARCH & DEVELOPMENT CO. LTD.Inventors: Ivan Michel Antolovic, Claudio Bruschini, Edoardo Charbon, Gur Lubin, Ron Tenne, Dan Oron, Uri Rossman
-
Patent number: 11983607Abstract: A quantum computing system, method and computer readable storage medium involve tuning a whispering-gallery mode optical resonator to support a resonance frequency associated with a transition frequency of an atom. Operation of a laser is controlled to cause the atom to be trapped adjacent the optical resonator and within the evanescent field portion. Based on an atom presence signal from an optical atom presence detector, an indication is provided that the atom is trapped adjacent the optical resonator. A frequency of a cooling laser is controlled to cool the atom, and the optical resonator is configured to define a closed loop-like mode including an evanescent field portion. The trapping laser is configured to cause the atom to be trapped adjacent the whispering-gallery mode resonator, and the cooling laser is configured to manipulate a state of the atom to thereby cool the atom.Type: GrantFiled: April 14, 2023Date of Patent: May 14, 2024Assignees: Yeda Research and Development Co. Ltd., Quantum Source Labs Ltd.Inventors: Gil Semo, Ziv Aqua, Oded Melamed, Dan Charash, Serge Rosenblum, Barak Dayan
-
Publication number: 20240148845Abstract: An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.Type: ApplicationFiled: November 21, 2023Publication date: May 9, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Yair REISNER, Noga OR-GEVA, Eran OPHIR, Yaki EIDELSTEIN, Rotem GIDRON BUDOVSKY